Jeonnam National University campus view.

Jeonnam National University campus view.

View original image

The Biomaterials Development Center at Jeonnam National University has established itself as the first "specialized institution for supporting medical device regulatory approval" among domestic universities, systematically assisting companies in obtaining regulatory approvals both domestically and internationally.


According to Jeonnam National University on April 8, the Biomaterials Development Center is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC International, AAALAC-I), and is equipped with a non-clinical testing environment that meets global standards. Based on this infrastructure, the center provides professional support for animal testing and preclinical data, which are essential requirements in international regulatory approval processes such as those by the U.S. Food and Drug Administration (FDA) and for European CE certification.


From 2019 to 2026, the center achieved results by supporting a total of 54 cases of domestic and international medical device regulatory approvals.


In particular, the center demonstrated outstanding performance in the field of overseas regulatory approvals, achieving a total of 26 global authorizations, including seven cases of FDA 510(k) approval, three cases of CE certification, and five cases of ISO certification. This is regarded as a prime example of a university-based research institute supporting not only basic research but also practical commercialization and global market entry.


This year, the center's research collaboration achievements became even more prominent. Hudenus Bio obtained the world’s first FDA 510(k) approval for an OCP (Octacalcium Phosphate)-based synthetic bone graft material, while S&M Medical’s body contouring medical device "NeoSculpt+" also received FDA approval with support from the center’s technology and regulatory assistance. These achievements are drawing attention as cases demonstrating both the technological competitiveness of domestic medical device companies and their potential for global market entry.


The Biomaterials Development Center is particularly strong in non-clinical testing using large animals. The center is able to obtain data under conditions similar to actual clinical settings, playing a crucial role in verifying the safety and efficacy of high-risk medical devices and implant products. This enables companies to secure highly reliable data required for regulatory approval processes and is expected to help shorten development periods and reduce costs.


The center goes beyond simple testing support and has established an integrated support system throughout the entire process, including ▲regulatory strategy development ▲regulatory consulting ▲test design ▲technical documentation support. Through this, it offers a "one-stop support platform" that connects the initial stages of research and development with global regulatory approvals.


Kang Seongsoo, Director of the Biomaterials Development Center at Jeonnam National University, stated, "In the medical device industry, the ability to respond to regulations, in addition to technological capabilities, directly translates into global competitiveness. Based on our accumulated experience in regulatory approval support and internationally standardized non-clinical testing infrastructure, we will further strengthen our full-cycle support to help domestic companies enter overseas markets with stability."



Meanwhile, the Biomaterials Development Center plans to expand its support to advanced biomaterials, regenerative medicine, and digital healthcare, and to strengthen its collaborative network with global regulatory bodies, thereby contributing to the development of the domestic medical device industry ecosystem.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing